03-07-01

UTILITY PATENT APPLICATION TRANSMITTAL

Docket No.: WM252.00

Page 1 of 2

Title: ELONGATED BIOPOLYMER STRUCTURE

CONTAINING FIBRIN

(Under 37 C.F.R. §1.53(b))

Express Mail Label No.: EL524824204US

APPLICATION ELEMENTS		ADDRESS TO: Assistant Commissioner for Patents					
		Box Patent Application 45					
INV	ENTORS: Yves Delmotte	Washington, D.C. 20231					
		·					
1.	X Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	10. X Information Disclosure X Copies of IDS Citations					
2.	X Specification [Total Pages 56]	11. Preliminary Amendment					
3.	X Drawing(s) (35 USC §113) [Total Pages (Fig. 1-14) 7]	12. Return Receipt Postcard (MPEP 503)					
4.	Signed Declaration [Total Pages]	13. Small Entity Statement(s)					
	a. Newly executed (original or copy)	14. Certified Copy of Priority Documents (s)					
	b. Copy from a prior application (37 CFR §1.63(d))	15a. Cancel in the application original claimsbefore calculating the filing fee					
	(Note Box 5 below) i. DELETION OF INVENTOR(S)	15b. Amend the specification by inserting before the first line the sentence:This is a Continuation,					
	Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)	Divisional, Continuation-in-part, of application, filed					
1		15c. I hereby verify that the attached papers are a true copy of the					
5.	Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application,	latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was					
1	from which a copy of the oath or declaration is supplied	signed. I hereby verify that the papers are a true copy of the latest					
	under Box 4b, is considered as being part of the disclosure of the accompanying application and is	signed prior application number, filed aAnd further that all statements made herein of my own knowledge					
	hereby incorporated by reference therein.	are true; and further that these statements were made with the knowledge that willful false statements and the like so made are					
6.	Nucleotide and/or Amino Acid Sequence Submission	punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false					
	statements may jeopardize the validity of the application or any						
a. b. c.	Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifiying identify of above copies	Patent issuing thereon.					
7.	Assignment Papers (cover sheet & document(s))						
1		15d. Other:					
8.	37 CFR §3.73(b) Statement Power of Attorney						
		15e. Other					
9.	English Translation Document						
16.	16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:						
	Continuation Divisional Continuati	on-in-part (CIP) of prior application No.:					



UTILITY PATENT APPLICATION TRANSMITTAL

Docket No.: WM252.00

Page 2 of 2

Title: ELONGATED BIOPOLYMER STRUCTURE

CONTAINING FIBRIN

(Under 37 C.F.R. §1.53(b))

Express Mail Label No.: EL524824204US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
The latest and the la	TOTAL CLAIMS (37 CFR 1.16(b))	36-20 =	16	X \$ 18 =	\$288.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	5-3 =	2	X \$ 80 =	\$160.00
	MULTIPLE DEPENDEN (37 CFR §1.16(d))	+ \$ 270 =	\$ 0		
				BASIC FEE (37 CFR §1.16(a))	\$710.00
ardiadi ardiadi				TOTAL =	\$1158.00

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket WM252.00). (For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. X Fees required under 37 CFR §1.16
- b. X Fees required under 37 CFR §1.17
- c. X Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	Janice Guthrie, Reg. No. 35,170
SIGNATURE	Suthere
DATE	March 6, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation P.O. Box 15210 Irvine, California 92614

Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL524824204US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on March 6, 2001.

S:\BAXTERAG-252.00-APPTRANS.DOC